US FDA to meet with stakeholders on epinephrine MDI phase-out
This article was originally published in RAJ Devices
Executive Summary
As the US Food and Drug Administration’s deadline draws near for phasing out currently approved over-the-counter epinephrine metered-dose inhalers, the agency is taking steps to educate the public about the phase-out and is gathering feedback on how this will affect the device users1.